Membranous Nephropathy - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510247804

Publication Date:

October 11, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Membranous nephropathy is also known as silent kidney problem and is considered as a form of glomerular disease. It is occurred when the glomeruli became damage and thickened that causes edema and heavy proteinuria. As a result, it leads to reduced kidney function and swelling. Membranous nephropathy can be caused by numerous factors such as autoimmune disease, use of certain medications such as nonsteroidal anti-inflammatory drugs, and exposure to certain infections such as hepatitis B, hepatitis C, and syphilis.
The global market for Membranous Nephropathy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Membranous Nephropathy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Membranous Nephropathy by region & country, by Type, and by Application.
The Membranous Nephropathy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Membranous Nephropathy.
麻豆原创 Segmentation
By Company
Pfizer Inc
F. Hoffmann-La Roche Ltd
Mylan N.V
Fresenius Kabi AG
Hikma Pharmaceuticals PLC
Novartis AG
Teva Pharmaceutical Industries Ltd
Bristol Myers Squibb Company
FibroGen, Inc
Mayne Pharma Group Limited
Segment by Type:
Alkylating Agents
Cyclophosphamide
Chlorambucil
Tacrolimus
MycophenolateMofetil
Other
Segment by Application
Hospial
Specialty Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Membranous Nephropathy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Membranous Nephropathy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Membranous Nephropathy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Membranous Nephropathy Product Introduction
1.2 Global Membranous Nephropathy 麻豆原创 Size Forecast
1.3 Membranous Nephropathy 麻豆原创 Trends & Drivers
1.3.1 Membranous Nephropathy Industry Trends
1.3.2 Membranous Nephropathy 麻豆原创 Drivers & Opportunity
1.3.3 Membranous Nephropathy 麻豆原创 Challenges
1.3.4 Membranous Nephropathy 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Membranous Nephropathy Players Revenue Ranking (2023)
2.2 Global Membranous Nephropathy Revenue by Company (2019-2024)
2.3 Key Companies Membranous Nephropathy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Membranous Nephropathy Product Offered
2.5 Key Companies Time to Begin Mass Production of Membranous Nephropathy
2.6 Membranous Nephropathy 麻豆原创 Competitive Analysis
2.6.1 Membranous Nephropathy 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Membranous Nephropathy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Membranous Nephropathy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Alkylating Agents
3.1.2 Cyclophosphamide
3.1.3 Chlorambucil
3.1.4 Tacrolimus
3.1.5 MycophenolateMofetil
3.1.6 Other
3.2 Global Membranous Nephropathy Sales Value by Type
3.2.1 Global Membranous Nephropathy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Membranous Nephropathy Sales Value, by Type (2019-2030)
3.2.3 Global Membranous Nephropathy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospial
4.1.2 Specialty Clinic
4.1.3 Other
4.2 Global Membranous Nephropathy Sales Value by Application
4.2.1 Global Membranous Nephropathy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Membranous Nephropathy Sales Value, by Application (2019-2030)
4.2.3 Global Membranous Nephropathy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Membranous Nephropathy Sales Value by Region
5.1.1 Global Membranous Nephropathy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Membranous Nephropathy Sales Value by Region (2019-2024)
5.1.3 Global Membranous Nephropathy Sales Value by Region (2025-2030)
5.1.4 Global Membranous Nephropathy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Membranous Nephropathy Sales Value, 2019-2030
5.2.2 North America Membranous Nephropathy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Membranous Nephropathy Sales Value, 2019-2030
5.3.2 Europe Membranous Nephropathy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Membranous Nephropathy Sales Value, 2019-2030
5.4.2 Asia Pacific Membranous Nephropathy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Membranous Nephropathy Sales Value, 2019-2030
5.5.2 South America Membranous Nephropathy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Membranous Nephropathy Sales Value, 2019-2030
5.6.2 Middle East & Africa Membranous Nephropathy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Membranous Nephropathy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Membranous Nephropathy Sales Value
6.3 United States
6.3.1 United States Membranous Nephropathy Sales Value, 2019-2030
6.3.2 United States Membranous Nephropathy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Membranous Nephropathy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Membranous Nephropathy Sales Value, 2019-2030
6.4.2 Europe Membranous Nephropathy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Membranous Nephropathy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Membranous Nephropathy Sales Value, 2019-2030
6.5.2 China Membranous Nephropathy Sales Value by Type (%), 2023 VS 2030
6.5.3 China Membranous Nephropathy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Membranous Nephropathy Sales Value, 2019-2030
6.6.2 Japan Membranous Nephropathy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Membranous Nephropathy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Membranous Nephropathy Sales Value, 2019-2030
6.7.2 South Korea Membranous Nephropathy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Membranous Nephropathy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Membranous Nephropathy Sales Value, 2019-2030
6.8.2 Southeast Asia Membranous Nephropathy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Membranous Nephropathy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Membranous Nephropathy Sales Value, 2019-2030
6.9.2 India Membranous Nephropathy Sales Value by Type (%), 2023 VS 2030
6.9.3 India Membranous Nephropathy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc
7.1.1 Pfizer Inc Profile
7.1.2 Pfizer Inc Main Business
7.1.3 Pfizer Inc Membranous Nephropathy Products, Services and Solutions
7.1.4 Pfizer Inc Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Inc Recent Developments
7.2 F. Hoffmann-La Roche Ltd
7.2.1 F. Hoffmann-La Roche Ltd Profile
7.2.2 F. Hoffmann-La Roche Ltd Main Business
7.2.3 F. Hoffmann-La Roche Ltd Membranous Nephropathy Products, Services and Solutions
7.2.4 F. Hoffmann-La Roche Ltd Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.2.5 F. Hoffmann-La Roche Ltd Recent Developments
7.3 Mylan N.V
7.3.1 Mylan N.V Profile
7.3.2 Mylan N.V Main Business
7.3.3 Mylan N.V Membranous Nephropathy Products, Services and Solutions
7.3.4 Mylan N.V Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.3.5 Fresenius Kabi AG Recent Developments
7.4 Fresenius Kabi AG
7.4.1 Fresenius Kabi AG Profile
7.4.2 Fresenius Kabi AG Main Business
7.4.3 Fresenius Kabi AG Membranous Nephropathy Products, Services and Solutions
7.4.4 Fresenius Kabi AG Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.4.5 Fresenius Kabi AG Recent Developments
7.5 Hikma Pharmaceuticals PLC
7.5.1 Hikma Pharmaceuticals PLC Profile
7.5.2 Hikma Pharmaceuticals PLC Main Business
7.5.3 Hikma Pharmaceuticals PLC Membranous Nephropathy Products, Services and Solutions
7.5.4 Hikma Pharmaceuticals PLC Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.5.5 Hikma Pharmaceuticals PLC Recent Developments
7.6 Novartis AG
7.6.1 Novartis AG Profile
7.6.2 Novartis AG Main Business
7.6.3 Novartis AG Membranous Nephropathy Products, Services and Solutions
7.6.4 Novartis AG Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis AG Recent Developments
7.7 Teva Pharmaceutical Industries Ltd
7.7.1 Teva Pharmaceutical Industries Ltd Profile
7.7.2 Teva Pharmaceutical Industries Ltd Main Business
7.7.3 Teva Pharmaceutical Industries Ltd Membranous Nephropathy Products, Services and Solutions
7.7.4 Teva Pharmaceutical Industries Ltd Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.7.5 Teva Pharmaceutical Industries Ltd Recent Developments
7.8 Bristol Myers Squibb Company
7.8.1 Bristol Myers Squibb Company Profile
7.8.2 Bristol Myers Squibb Company Main Business
7.8.3 Bristol Myers Squibb Company Membranous Nephropathy Products, Services and Solutions
7.8.4 Bristol Myers Squibb Company Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.8.5 Bristol Myers Squibb Company Recent Developments
7.9 FibroGen, Inc
7.9.1 FibroGen, Inc Profile
7.9.2 FibroGen, Inc Main Business
7.9.3 FibroGen, Inc Membranous Nephropathy Products, Services and Solutions
7.9.4 FibroGen, Inc Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.9.5 FibroGen, Inc Recent Developments
7.10 Mayne Pharma Group Limited
7.10.1 Mayne Pharma Group Limited Profile
7.10.2 Mayne Pharma Group Limited Main Business
7.10.3 Mayne Pharma Group Limited Membranous Nephropathy Products, Services and Solutions
7.10.4 Mayne Pharma Group Limited Membranous Nephropathy Revenue (US$ Million) & (2019-2024)
7.10.5 Mayne Pharma Group Limited Recent Developments
8 Industry Chain Analysis
8.1 Membranous Nephropathy Industrial Chain
8.2 Membranous Nephropathy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Membranous Nephropathy Sales Model
8.5.2 Sales Channel
8.5.3 Membranous Nephropathy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Pfizer Inc
F. Hoffmann-La Roche Ltd
Mylan N.V
Fresenius Kabi AG
Hikma Pharmaceuticals PLC
Novartis AG
Teva Pharmaceutical Industries Ltd
Bristol Myers Squibb Company
FibroGen, Inc
Mayne Pharma Group Limited

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.